The reasoning behind this category is that most growth hormone is released during deep sleep, so a compound that raises growth hormone should improve sleep. That inference runs the causal arrow backwards, and it is worth spelling out before anything else on this page. Batch certificates are published at /coa.
Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab 2006;91(3):799–805. PMID 16352683; Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. JCEM 2006;91(12):4792–7. PMID 17018654; Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139(5):552–61. PMID 9849822
Deep sleep drives GH release, not the reverse
The observation is real and long-established: growth hormone secretion is strongly associated with slow-wave sleep. That is why the two get linked.
But the established direction is that sleep architecture drives the hormone pulse. It does not follow that raising the hormone pharmacologically improves the sleep. Those are different claims, and only the first is well supported.
No published human trial of CJC-1295 or ipamorelin has measured sleep as an endpoint. Not sleep latency, not slow-wave duration, not subjective quality, not polysomnography. The human work on these compounds measured hormone concentrations, and that is all it measured.
What was measured
Teichman et al. (2006) ran two randomised, placebo-controlled, double-blind ascending-dose trials of 28 and 49 days in healthy adults aged 21 to 61. A single subcutaneous dose raised mean plasma growth hormone two- to ten-fold for six days or more and IGF-1 by 1.5- to three-fold for nine to eleven days, with a half-life of 5.8 to 8.1 days.
A separate 2006 paper by Ionescu and Frohman asked whether the natural pulsatile pattern of GH secretion survives continuous stimulation by CJC-1295, and reported that it does. That matters here more than elsewhere, because a compound that flattened the nocturnal pulse would be working against the physiology the sleep rationale rests on — and this study addressed the question directly rather than assuming either answer.
Ipamorelin’s characterisation is preclinical, with no published human dose-ranging trial.
One product, and we would rather say so
This goal lists a single pen (what is in the pen). We could pad the category by filing other compounds under it on loose reasoning, which is what a thin category page usually does. We have not, because the honest set is one.
If a sleep-focused product is what you want, the reasonable position is that this category has a mechanistic rationale and no sleep-endpoint evidence (the muscle page covers the same pen). That may still be interesting to you. It should not be presented as established.
The timing convention, and what it is based on
The protocol Body Pharm publishes for its own pen — one dose before bed, five nights per week, on an empty stomach — is timed to coincide with the natural nocturnal GH pulse, and food (particularly carbohydrate) blunts the GH response. That is the supplier’s stated protocol and the reasoning behind it, not a finding from any of the trials cited above.
What is not known
No published human trial of the combination. No long-term human safety data for either compound. No marketing authorisation, therefore no post-marketing surveillance collecting adverse events — so an absence of reports is not evidence of absence. Both are prohibited at all times under WADA.
Further reading: growth hormone peptides, CJC-1295 vs Ipamorelin, dosing in the published literature, reported adverse events.
